GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Short-Term Debt

GeneTether Therapeutics (XCNQ:GTTX) Short-Term Debt : C$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Short-Term Debt?

GeneTether Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2023 was C$0.00 Mil.


GeneTether Therapeutics Short-Term Debt Historical Data

The historical data trend for GeneTether Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Short-Term Debt Chart

GeneTether Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Short-Term Debt
0.16 - - -

GeneTether Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

GeneTether Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


GeneTether Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneTether Therapeutics (XCNQ:GTTX) Business Description

Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines